
Ovid Therapeutics (NASDAQ:OVID) expects several clinical updates over the next year as it advances an epilepsy drug and a separate experimental treatment initially aimed at schizophrenia, President and CEO Meg Alexander said at the 2026 UBS Biopharma Conference.
The company’s lead epilepsy candidate, OV329, is being studied in adults with focal epilepsy and in a separate photosensitivity study. Ovid is also developing a pediatric formulation for children with tuberous sclerosis complex and, potentially, infants with spasms.
For its second major program, Ovid expects to finish a Phase 1 study of OV4071 around the end of the first quarter of 2027 and plans to begin a Phase 2 acute schizophrenia study around the middle of that year, Alexander said.
Epilepsy program approaches readouts
OV329 inhibits an enzyme that breaks down GABA, an inhibitory neurotransmitter in the brain. Alexander said the mechanism had previously been used to reduce seizures, but the earlier drug carried significant safety and tolerability problems, including irreversible vision loss.
Ovid designed OV329 to improve on that profile. Alexander said animal studies showed that, unlike the earlier drug, OV329 cleared from eye tissue without accumulating and that the retina remained intact at a scaled therapeutic dose. Those findings are preclinical and do not establish the drug’s long-term safety in patients.
About 100 people have received OV329 to date, Alexander said. She described the tolerability observed at planned clinical doses as encouraging, while noting adverse events that included sedation, drowsiness and headache.
Ovid expects results in the first quarter of 2027 from an open-label photosensitivity study testing the planned Phase 2 dose and doses above and below it. Alexander said the study is intended to help assess anticonvulsant activity and inform dosing for potential pivotal studies.
A global Phase 2 study in adults with focal epilepsy is underway, with a readout expected in the second half of 2027. Its primary measure will be seizure reduction from monthly baseline, Alexander said.
Ovid also plans to start an open-label study in children with tuberous sclerosis complex at the end of 2026. The study will assess safety and help confirm pediatric dosing before a planned infantile spasms study in 2027.
Schizophrenia candidate advances through Phase 1
OV4071 is an oral direct activator of KCC2, a transporter involved in regulating neuronal inhibition. Alexander said Ovid’s initial focus is psychosis, although the company is also investigating the target’s potential in other conditions.
Alexander cited animal studies in which OV4071 showed activity in models associated with positive, negative and cognitive symptoms of schizophrenia. She cautioned that psychiatric animal models are not perfect proxies for the complexity of human conditions.
Ovid also plans to start a ketamine challenge study to assess the drug’s effects using biomarkers, including electrophysiology measures. Alexander said the company expects that study to conclude around the end of the first quarter of 2027.
The planned Phase 2 acute schizophrenia study will primarily examine positive symptoms. Alexander said the company views the indication as a potential proof of concept for KCC2 activation, with further work needed to assess its broader therapeutic potential.
About Ovid Therapeutics (NASDAQ:OVID)
Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing medicines for epilepsies and other neurological disorders. Its work targets conditions with significant unmet treatment needs, including rare and difficult-to-treat seizure disorders. The company’s lead development program, OV329, is an investigational GABA aminotransferase inhibitor being studied as a potential treatment for seizures, including infantile spasms and focal-onset seizures. Ovid’s pipeline and research programs may change as clinical development progresses.
